European Stroke Prevention Study "ESPS-2"


Phase N/A Results


The 24-month stroke rate was 12.9% in the aspirin-alone group, 12.2% in the dipyridamole-alone group, 9.9% in the combination group and 15.8% in the placebo group. This difference among the four groups was significant (p<0.001). The results regarding the endpoint of stroke or death were similar but there was no significant difference among the groups for the endpoint of death (p=0.616). Stroke risk was significantly reduced by 18.1% in the aspirin-alone group, by 16.3% in the dipyridamole-alone group, and by 37.0% in the combination group compared to the placebo group.